Thromboxane (TX) synthase metabolizes the cyclooxygenase product, prostanglandin HZ, into thromboxane A2 (TXA.2), which can cause vessel constriction, platelet activation, and aggregation. We have demonstrated that TX synthase expression is stimulated during prostate cancer progression and that this enzyme is involved in controlling tumor cell motility. We hypothesize that the stimulation of TX synthase expression is an integral part of prostate carcinogenesis and TX synthase confers upon prostate cancer cells with increased motility and invasiveness, and also with increased capability to elaborate host tissues such as the hemostatic system, especially platelets, to facilitate tumor progression and metastasis. The three specific aims present a road map to define when and how TX synthase is stimulated during prostate cancer initiation and progression, what role TX synthase and TXA2 play, and whether or not the hemostatic system is impeded to facilitate prostate tumor progression and metastasis through thrombane signaling loop. In the first specific aim, we will define the pattern of TX synthase expression during prostate cancer initiation and progression using TRAMP mouse model for prostate cancer. In the specific aim 2, we will characterize TXA.2 receptors expressed in prostate cancer cells and further study the signaling pathway involved for TXA2 to control cytoskeleton and motility. In the third specific aim, we will over express or knock out TX synthase expression in tumor cells and examine the resultant changes in cell phenotypes in vitro, interaction with platelets, and tumor formation, progression, and metastasis in vivo. We believe the proposed studies will provide significant insights into the process of prostate cancer initiation and progression and also afford us an exciting avenue for intervention previously unexplored. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA114051-01A1
Application #
7033231
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Woodhouse, Elizabeth
Project Start
2006-08-15
Project End
2011-07-31
Budget Start
2006-08-15
Budget End
2007-07-31
Support Year
1
Fiscal Year
2006
Total Cost
$397,918
Indirect Cost
Name
Wayne State University
Department
Pathology
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Tucker, Stephanie C; Honn, Kenneth V (2013) Emerging targets in lipid-based therapy. Biochem Pharmacol 85:673-88
Ekambaram, Prasanna; Lambiv, Wanyu; Cazzolli, Rosanna et al. (2011) The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer Metastasis Rev 30:397-408
Nie, Daotai; Guo, Yande; Yang, Dianer et al. (2008) Thromboxane A2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho. Cancer Res 68:115-21
Wang, Man-Tzu; Honn, Kenneth V; Nie, Daotai (2007) Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 26:525-34